Yarrow Bioscience, Inc. (YARW)
37.40
-0.60
(-1.58%)
USD |
NASDAQ |
Aug 28, 16:00
37.40
0.00 (0.00%)
After-Hours: 17:27
Yarrow Bioscience Net Income (Quarterly) : -2.899M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.899M |
| March 31, 2026 | -3.585M |
| December 31, 2025 | -4.96M |
| September 30, 2025 | -7.426M |
| June 30, 2025 | -5.747M |
| March 31, 2025 | -8.603M |
| December 31, 2024 | -12.01M |
| September 30, 2024 | -12.16M |
| June 30, 2024 | -9.395M |
| March 31, 2024 | -6.241M |
| December 31, 2023 | -6.152M |
| September 30, 2023 | -6.071M |
| June 30, 2023 | -10.04M |
| March 31, 2023 | -5.612M |
| December 31, 2022 | -7.761M |
| September 30, 2022 | -9.255M |
| June 30, 2022 | -8.235M |
| March 31, 2022 | -8.694M |
| December 31, 2021 | -8.372M |
| September 30, 2021 | -14.28M |
| Date | Value |
|---|---|
| June 30, 2021 | -10.68M |
| March 31, 2021 | -10.88M |
| December 31, 2020 | -23.18M |
| September 30, 2020 | -24.71M |
| June 30, 2020 | -167.44M |
| March 31, 2020 | -40.23M |
| December 31, 2019 | -37.82M |
| September 30, 2019 | -23.16M |
| June 30, 2019 | -18.99M |
| March 31, 2019 | -15.20M |
| December 31, 2018 | -17.59M |
| September 30, 2018 | -12.85M |
| June 30, 2018 | -8.347M |
| March 31, 2018 | -12.66M |
| December 31, 2017 | -9.277M |
| September 30, 2017 | -8.173M |
| June 30, 2017 | -6.153M |
| March 31, 2017 | -5.474M |
| December 31, 2016 | -4.837M |
| September 30, 2016 | -3.398M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Oramed Pharmaceuticals, Inc. | 78.16M |
| NRX Pharmaceuticals, Inc. | -16.52M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.097M |
| Total Expenses (Quarterly) | 2.996M |
| EPS Diluted (Quarterly) | -3.504 |
| Enterprise Value | 2.470M |
| Gross Profit Margin (Quarterly) | 93.81% |
| Profit Margin (Quarterly) | -2.99K% |
| Earnings Yield | -62.72% |
| Normalized Earnings Yield | -62.72 |